Search - tctmd.com

Displaying 101 - 120 of 449

Sort: Relevancy | Date

In-Stent Restenosis Accounts for 10% of All PCIs, Contemporary National Analysis Shows

News Daily News

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

September 24, 2020

PCI of a Last Remaining Patent Vessel Is Rare and Risky, UK Data Confirm

News Daily News

PCI of a Last Remaining Patent Vessel Is Rare and Risky, UK Data Confirm

September 08, 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

September 03, 2020

CABG Loses Survival Advantage in Women at 10 Years: SYNTAXES

News Daily News

CABG Loses Survival Advantage in Women at 10 Years: SYNTAXES

Yael L. Maxwell

August 20, 2020

FFR Deferral of Nonculprit Lesions Riskier in ACS vs Stable Angina

News Daily News

FFR Deferral of Nonculprit Lesions Riskier in ACS vs Stable Angina

August 03, 2020

For Cardiac CT, COVID-19 Has Toppled Silos and Paved the Way for Change

News Conference News SCCT 2020

For Cardiac CT, COVID-19 Has Toppled Silos and Paved the Way for Change

Yael L. Maxwell

July 28, 2020

Complete Revascularization May Top Culprit-Only PCI Across ACS Types

News Daily News

Complete Revascularization May Top Culprit-Only PCI Across ACS Types

July 08, 2020

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

News Daily News

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

Michael O'Riordan

July 07, 2020

July 2020 News Roundup

News Daily News

July 2020 News Roundup

July 01, 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

News Conference News SCAI 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

May 15, 2020

Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes

News Features

Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes

Michael O'Riordan

May 12, 2020

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

Functionally Significant Nonculprit Lesions Pose Risk in STEMI Patients

News Daily News

Functionally Significant Nonculprit Lesions Pose Risk in STEMI Patients

Michael O'Riordan

April 21, 2020

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

March 31, 2020

First Point-of-Care hs-Troponin I Assay Matches Lab-Based Tests

News Daily News

First Point-of-Care hs-Troponin I Assay Matches Lab-Based Tests

March 10, 2020

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

News Daily News

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

February 14, 2020

ACS After TAVR a Unique Condition With Poor Prognosis

News Daily News

ACS After TAVR a Unique Condition With Poor Prognosis

February 05, 2020

FFR for Stable Patients With Intermediate CAD? VA Analysis Stokes Debate

News Daily News

FFR for Stable Patients With Intermediate CAD? VA Analysis Stokes Debate

Michael O'Riordan

January 27, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.